July 16, 2026 |
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they examine the evolving role of congresses, from experience design and technology to strategy, measurement and commercial impact.

Simon Davenport, Global Head of Environments at Inizio Engage, explores the characteristics that set the most successful congress experiences apart. Drawing on observations from the exhibition floor, the article highlights three key principles: creating a clear and consistent scientific narrative, designing interactions that genuinely enhance engagement rather than relying on technology for its own sake, and building flexible experiences that allow HCPs to engage at different levels. The article explains why thoughtful experience design is becoming increasingly important as congress environments grow more competitive.
Read full article here.
Nick Bellomo, VP of Experience and Technology at Inizio Medical, examines the technology and engagement innovations that stood out across ASCO® 2026. From immersive LED environments and AI-powered interactions to tactile, low-tech activations, the article explores how organisations are rethinking the use of technology to create more meaningful scientific engagement. It concludes that the most effective congress experiences combine creativity with purposeful design to strengthen scientific communication and generate valuable behavioural insights.
Read full article here.
Lynsey Holbrook, Global Client Development Director at Inizio Engage, focuses on the growing complexity of congress planning and the challenge of demonstrating return on investment. The article explores why many pharmaceutical organisations struggle to connect strategy, execution and measurement, despite increasing investment in congresses. It outlines how a more connected approach can help teams align stakeholders, create more coordinated delegate experiences and measure the activities that drive meaningful scientific and commercial outcomes.
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.
A few key considerations for conducting healthcare market research in the Gulf
Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a…
Live webinar: Thursday 30th March 10:00 EDT / 15:00 BST / 16:00 CEST
Published in eyeforpharma February 2017 by Marc Yates
Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research…
Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and…
SLE is a progressive and debilitating disease which affects 5 million people worldwide.
Pegasus, an Ashfield company, part of UDG Healthcare plc, is proud to announce the launch of its new propriety model for planning in health – CHANGE – which was developed…
Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics
